Bright Minds Biosciences DRUG
NASDAQ DRUG
$50.69 +1.48 (+3.01%)
At close: Oct 2, 2026 · 4:00 PM EDT

Bright Minds Biosciences (DRUG) Liabilities and Shareholders Equity (2019 - 2026)

Updated

Bright Minds Biosciences (DRUG) recorded Liabilities and Shareholders Equity of $224.35 million in fiscal Q3 2026 (quarter ended Jun 30, 2026), up 492.1% from $37.89 million a year earlier but down 1.5% from the prior quarter.

Analysis

Bright Minds Biosciences (DRUG) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

At the end of FY2025 (ended Sep 30, 2025), Bright Minds Biosciences reported Liabilities and Shareholders Equity of $60.4 million.

  • Annual Liabilities and Shareholders Equity has a five-year compound annual growth rate of 147.2% (FY2020 to FY2025).
  • Across earlier fiscal years, Liabilities and Shareholders Equity came in at $4.49 million in FY2024 (-12.0%), $5.1 million in FY2023 (-46.1%), $9.47 million in FY2022 (-40.3%) and $15.86 million in FY2021.
  • Quarterly Liabilities and Shareholders Equity has ranged from $4.47 million in fiscal Q4 2024 to $227.78 million in fiscal Q2 2026 over the past five years.
  • On a year-over-year basis, Liabilities and Shareholders Equity has increased for three consecutive quarters, with growth averaging 454.0% over the last seven quarters.
  • Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 726.4% in fiscal Q1 2025, against a decline of 61.7% in fiscal Q3 2022 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at $227.78 million (Q2 2026), $65.17 million (Q1 2026) and $61.34 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 142.28 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 201.06 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 135.12 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 129.80 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 122.03 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 115.83 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 95.64 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 49.36 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 201.13 Bn
10 Bright Minds Biosciences 375.76 Mn 375.76 Mn - 224.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 224.35 Mn
Mar 31, 2026 227.78 Mn
Dec 31, 2025 65.17 Mn
Sep 30, 2025 61.34 Mn
Jun 30, 2025 37.89 Mn
Mar 31, 2025 39.35 Mn
Dec 31, 2024 41.80 Mn
Sep 30, 2024 4.47 Mn
Jun 30, 2024 4.59 Mn
Mar 31, 2024 4.85 Mn
Dec 31, 2023 5.06 Mn
Sep 30, 2023 5.13 Mn
Jun 30, 2023 6.30 Mn
Mar 31, 2023 7.39 Mn
Dec 31, 2022 8.51 Mn
Sep 30, 2022 9.27 Mn
Jun 30, 2022 6.92 Mn
Mar 31, 2022 9.29 Mn
Dec 31, 2021 12.23 Mn
Sep 30, 2021 15.92 Mn
API Access

Bright Minds Biosciences Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=DRUG&period=max&api_key=YOUR_API_KEY